Tejon Ranch Co. (the “Company”) (NYSE:TRC), a diversified real estate development and agriculture company, today issued a ...
Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...
The letter suggests an impact guide to understand the rules and includes recommendations based on a roundtable conversation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback